DS
DSFIR.AS DSM-Firmenich AG
- Market cap
- EUR 26.0B
- P/E
- -
- P/B
- 1.45x
- ROE
- 3.6%
- Dividend yield
- 2.76%
- Fundamental score
- 2.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is DSFIR.AS undervalued?
Graham numberThe Graham number of DSM-Firmenich AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DSM-Firmenich AG fundamental analysis
11 of 22 checks passedROE 0/2
Low return on equity (3.6%), below 10%.
ROA 1/1
Return on assets (2.1%) is above the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-541.2%) is below the industry median (1.2%).
Revenue Growth 1/2
Revenue grew 2.5% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (38.0%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (1.4x) is above the industry median (0.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (2.8%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 2/2
Dividends paid without a cut of more than 10% for 11 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
DSM-Firmenich AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, incl…
Full company profileDSM-Firmenich AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DSM-Firmenich AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.92B | 8.63B | 9.27B | 8.00B | 8.11B | 11.4B | 8.39B | 10.6B | 9.05B | 9.03B | 14.0B |
| Gross Profit | 2.66B | 2.93B | 3.41B | 2.76B | 2.78B | 4.19B | 2.69B | 2.61B | 3.55B | 3.53B | 5.69B |
| Operating Income | 625M | 797M | 1.21B | 807M | 662M | 751M | 725M | 7.00M | 667M | 711M | 1.20B |
| EBITDA | 1.08B | 1.25B | 1.67B | 1.33B | 1.26B | 1.51B | 1.38B | 1.31B | 1.60B | 1.61B | 2.61B |
| Net Income | 645M | 1.76B | 1.07B | 675M | 448M | 872M | 460M | 2.14B | 250M | -1.08B | 636M |
| EPS | 3.67 | 10 | 6.06 | 3.82 | 2.60 | 5.04 | 2.65 | 9.16 | 0.94 | -4.17 | 2.54 |
| Balance Sheet | |||||||||||
| Total Assets | 13.0B | 12.8B | 13.6B | 13.4B | 14.3B | 16.0B | 17.4B | 34.3B | 33.7B | 29.3B | 30.4B |
| Total Liabilities | 6.78B | 5.74B | 5.83B | 5.61B | 6.86B | 6.62B | 6.56B | 11.2B | 11.1B | 10.9B | 12.5B |
| Shareholders' Equity | 6.07B | 6.96B | 7.78B | 7.73B | 7.40B | 9.32B | 10.7B | 22.9B | 22.5B | 18.2B | 17.8B |
| Cash & Short-term Investments | 1.55B | 1.85B | 2.56B | 1.49B | 914M | 2.05B | 2.88B | 2.56B | 2.72B | 1.90B | 2.31B |
| Total Debt | 3.47B | 2.65B | 2.66B | 2.66B | 3.59B | 3.10B | 3.06B | 4.83B | 5.28B | 5.66B | 6.77B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.02B | 996M | 1.39B | 1.39B | 1.49B | 1.43B | 923M | 1.27B | 1.78B | 1.39B | 1.42B |
| Capital Expenditure | 413M | 449M | 565M | 520M | 458M | 433M | 644M | 555M | 764M | 764M | 1.39B |
| Free Cash Flow | 605M | 547M | 826M | 865M | 1.04B | 994M | 279M | 710M | 1.01B | 624M | 33.0M |
| Ratios | |||||||||||
| ROE | 10.6% | 25.3% | 13.7% | 8.7% | 6.1% | 9.4% | 4.3% | 9.3% | 1.1% | -5.9% | 3.6% |
| ROA | 5.0% | 13.8% | 7.8% | 5.0% | 3.1% | 5.4% | 2.6% | 6.2% | 0.7% | -3.7% | 2.1% |
| Net Profit Margin | 8.1% | 20.4% | 11.5% | 8.4% | 5.5% | 7.6% | 5.5% | 20.1% | 2.8% | -12.0% | 4.5% |
| Debt to Equity | 0.57x | 0.38x | 0.34x | 0.34x | 0.48x | 0.33x | 0.29x | 0.21x | 0.23x | 0.31x | 0.38x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DSM-Firmenich AG dividends
- Dividend yield
- 2.76%
- Forward dividend
- 2.50 EUR
- Payout ratio
- -
- Ex-dividend date
- May 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 718M | 2.77 | - |
| 2024 | EUR 667M | 2.52 | 266.8% |
| 2023 | EUR 582M | 2.50 | 27.2% |
| 2022 | EUR 345M | 1.99 | 75.0% |
| 2021 | EUR 266M | 1.54 | 30.5% |
| 2020 | EUR 289M | 1.68 | 64.5% |
| 2019 | EUR 291M | 1.65 | 43.1% |
| 2018 | 225M | 1.28 | 21.0% |
| 2017 | 200M | 1.14 | 11.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns DSM-Firmenich AG
- Insiders 9.49%
- Institutions 53.36%
- Public & others 37.16%
- Shares outstanding 244M
- Free float 225M
DSM-Firmenich AG company profile
- Company name
- DSM-Firmenich AG
- Ticker
- DSFIR.AS
- ISIN
- CH1216478797
- Exchange
- Euronext Amsterdam
- Sector
- Basic Materials
- Industry
- Personal Care Products
- Employees
- 20,786
- Fiscal year end
- December
- Address
- Wurmisweg 576, Kaiseraugst, Switzerland, 4303
- Phone
- 41 61 815 8888
- Website
- dsm-firmenich.com
About DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. DSM-Firmenich AG was founded in 1902 and is based in Kaiseraugst, Switzerland.
DSM-Firmenich AG management
10- Mr. Dimitri de VreezeChief Executive Officer · born 1967
- Mr. Ralf SchmeitzChief Financial Officer · born 1972
- Mr. Emmanuel ButstraenBU President of Perfumery & Beauty and COO · born 1968
- Dr. Sarah ReisingerChief Science & Research Officer · born 1979
- Mr. Dave HuizingSenior Vice President of Investor Relations
- Ms. Laetitia PictetChief Legal, Risk & Compliance Officer · born 1970
- Ms. Nikeisha van SleeuwenChief Human Resources Officer
- Mr. Philip EykermanChief Strategy, M&A and Transformation Officer · born 1969
- Ms. Jane SinclairAdvisor to the CEO · born 1962
- Ms. Katharina StenholmChief Sustainability Officer · born 1967